Last 12 months
Inside the activity.
0 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 29, 2024 Filed Jan 31, 2024 21:56 UTC |
SCHWARTZ BRIANDirector · Interim Chief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001104659-24-008862 · tm244773-1_4seq1.xml · derivative · entry 2 SCHWARTZ BRIAN · CIK 0001431322 · Director · Interim Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-01-29 F2 · price: These securities were granted to Dr. Schwartz in connection with his appointment as interim Chief Medical Officer of Cyclacel Pharmaceuticals, Inc. F3 · derivative.exercise_date: The shares underlying the option vest in equal monthly installments beginning on February 29, 2024, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 21:56 UTC |
SCHWARTZ BRIANDirector · Interim Chief Medical Officer
|
GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-008862 · tm244773-1_4seq1.xml · nonDerivative · entry 1 SCHWARTZ BRIAN · CIK 0001431322 · Director · Interim Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,205 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal monthly installments beginning on February 29, 2024, subject to the Reporting Person's continued service through the applicable vesting date. F2 · price: These securities were granted to Dr. Schwartz in connection with his appointment as interim Chief Medical Officer of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| December 21, 2023 Filed Dec 26, 2023 21:05 UTC |
McBarron PaulDirector · See Remarks
|
PurchaseWarrants (right to buy) · Derivative | 1,886 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001104659-23-129186 · tm2333679-1_4seq1.xml · derivative · entry 2 McBarron Paul · CIK 0001357397 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,886 Underlying: Common Stock · 1,886 shares Expires 2030-12-21 F2 · price: Each share of common stock was purchased with an accompanying warrant at an aggregate purchase price of $3.315 per share and accompanying warrant. Read SEC document |
| December 21, 2023 Filed Dec 26, 2023 21:05 UTC |
McBarron PaulDirector · See Remarks
|
PurchaseCommon Stock | 1,886 | $3.32 | $6,252.09 |
DisclosureSEC source: 0001104659-23-129186 · tm2333679-1_4seq1.xml · nonDerivative · entry 1 McBarron Paul · CIK 0001357397 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,378 F1 · security: The Reporting Person purchased unregistered shares of the Issuer's common stock in a private placement, pursuant to a Securities Purchase Agreement between the Reporting Person and the Issuer. Read SEC document |
| December 21, 2023 Filed Dec 26, 2023 21:05 UTC |
Rombotis Spiro GeorgeDirector · President and CEO
|
PurchaseWarrants (right to buy) · Derivative | 6,070 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001104659-23-129185 · tm2333679-2_4seq1.xml · derivative · entry 2 Rombotis Spiro George · CIK 0001357396 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,070 Underlying: Common Stock · 6,070 shares Expires 2030-12-21 F2 · price: Each share of common stock was purchased with an accompanying warrant at an aggregate purchase price of $3.315 per share and accompanying warrant. Read SEC document |
| December 21, 2023 Filed Dec 26, 2023 21:05 UTC |
Rombotis Spiro GeorgeDirector · President and CEO
|
PurchaseCommon Stock | 6,070 | $3.32 | $20,122.05 |
DisclosureSEC source: 0001104659-23-129185 · tm2333679-2_4seq1.xml · nonDerivative · entry 1 Rombotis Spiro George · CIK 0001357396 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,658 F1 · security: The Reporting Person purchased unregistered shares of the Issuer's common stock in a private placement, pursuant to a Securities Purchase Agreement between the Reporting Person and the Issuer. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:58 UTC |
Rombotis Spiro GeorgeDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001104659-23-077661 · tm2320411-9_4seq1.xml · derivative · entry 1 Rombotis Spiro George · CIK 0001357396 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2033-06-30 F1 · price: The reporting person received an award of 110,000 options on June 30, 2023, which shall vest in full on June 30, 2026, provided, however, that if certain clinical milestones are achieved then such options shall vest in full earlier in connection with such achievement. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:57 UTC |
BARKER SAM LDirector
|
GrantStock Option (right to buy) · Derivative | 42,438 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001104659-23-077660 · tm2320411-8_4seq1.xml · derivative · entry 2 BARKER SAM L · CIK 0001226877 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,438 Underlying: Common Stock · 42,438 shares Expires 2033-06-30 F2 · price: These securities were granted to Dr. Barker for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:57 UTC |
BARKER SAM LDirector
|
GrantCommon Stock | 21,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-077660 · tm2320411-8_4seq1.xml · nonDerivative · entry 1 BARKER SAM L · CIK 0001226877 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,415 F1 · shares: The reporting person received an award of 21,219 restricted stock units on June 30, 2023, which shall vest in full on June 30, 2024. F2 · price: These securities were granted to Dr. Barker for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:57 UTC |
Spiegel Robert J.Director
|
GrantStock Option (right to buy) · Derivative | 42,438 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001104659-23-077658 · tm2320411-7_4seq1.xml · derivative · entry 2 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,438 Underlying: Common Stock · 42,438 shares Expires 2033-06-30 F2 · price: These securities were granted to Dr. Spiegel for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:57 UTC |
Spiegel Robert J.Director
|
GrantCommon Stock | 21,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-077658 · tm2320411-7_4seq1.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,415 F1 · shares: The reporting person received an award of 21,219 restricted stock units on June 30, 2023, which shall vest in full on June 30, 2024. F2 · price: These securities were granted to Dr. Spiegel for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:57 UTC |
McBarron PaulDirector · See Remarks
|
GrantStock Option (right to buy) · Derivative | 70,200 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001104659-23-077657 · tm2320411-6_4seq1.xml · derivative · entry 1 McBarron Paul · CIK 0001357397 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,200 Underlying: Common Stock · 70,200 shares Expires 2033-06-30 F1 · price: The reporting person received an award of 70,200 options on June 30, 2023, which shall vest in full on June 30, 2026, provided, however, that if certain clinical milestones are achieved then such options shall vest in full earlier in connection with such achievement. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:56 UTC |
Kirschbaum MarkChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 70,200 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001104659-23-077656 · tm2320411-5_4seq1.xml · derivative · entry 1 Kirschbaum Mark · CIK 0001830211 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,200 Underlying: Common Stock · 70,200 shares Expires 2033-06-30 F1 · price: The reporting person received an award of 70,200 options on June 30, 2023, which shall vest in full on June 30, 2026, provided, however, that if certain clinical milestones are achieved then such options shall vest in full earlier in connection with such achievement. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:56 UTC |
Walker Karin LDirector
|
GrantStock Option (right to buy) · Derivative | 42,438 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001104659-23-077655 · tm2320411-4_4seq1.xml · derivative · entry 2 Walker Karin L · CIK 0001559422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,438 Underlying: Common Stock · 42,438 shares Expires 2033-06-30 F2 · price: These securities were granted to Ms. Walker for her services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:56 UTC |
Walker Karin LDirector
|
GrantCommon Stock | 21,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-077655 · tm2320411-4_4seq1.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,602 F1 · shares: The reporting person received an award of 21,219 restricted stock units on June 30, 2023, which shall vest in full on June 30, 2024. F2 · price: These securities were granted to Ms. Walker for her services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:55 UTC |
HENNEY CHRISTOPHER SDirector
|
GrantStock Option (right to buy) · Derivative | 42,438 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001104659-23-077651 · tm2320411-2_4seq1.xml · derivative · entry 2 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,438 Underlying: Common Stock · 42,438 shares Expires 2033-06-30 F2 · price: These securities were granted to Dr. Henney for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:55 UTC |
HENNEY CHRISTOPHER SDirector
|
GrantCommon Stock | 21,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-077651 · tm2320411-2_4seq1.xml · nonDerivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,415 F1 · shares: The reporting person received an award of 21,219 restricted stock units on June 30, 2023, which shall vest in full on June 30, 2024. F2 · price: These securities were granted to Dr. Henney for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:56 UTC |
Ferguson Kenneth M.Director
|
GrantStock Option (right to buy) · Derivative | 42,438 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001104659-23-077652 · tm2320411-3_4seq1.xml · derivative · entry 2 Ferguson Kenneth M. · CIK 0001934344 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,438 Underlying: Common Stock · 42,438 shares Expires 2033-06-30 F2 · price: These securities were granted to Dr. Ferguson for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:56 UTC |
Ferguson Kenneth M.Director
|
GrantCommon Stock | 21,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-077652 · tm2320411-3_4seq1.xml · nonDerivative · entry 1 Ferguson Kenneth M. · CIK 0001934344 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,952 F1 · shares: The reporting person received an award of 21,219 restricted stock units on June 30, 2023, which shall vest in full on June 30, 2024. F2 · price: These securities were granted to Dr. Ferguson for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:55 UTC |
SCHWARTZ BRIANDirector
|
GrantStock Option (right to buy) · Derivative | 42,438 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001104659-23-077650 · tm2320411-1_4seq1.xml · derivative · entry 2 SCHWARTZ BRIAN · CIK 0001431322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,438 Underlying: Common Stock · 42,438 shares Expires 2033-06-30 F2 · price: These securities were granted to Dr. Schwartz for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:55 UTC |
SCHWARTZ BRIANDirector
|
GrantCommon Stock | 21,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-077650 · tm2320411-1_4seq1.xml · nonDerivative · entry 1 SCHWARTZ BRIAN · CIK 0001431322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,602 F1 · shares: The reporting person received an award of 21,219 restricted stock units on June 30, 2023, which shall vest in full on June 30, 2024. F2 · price: These securities were granted to Dr. Schwartz for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 21:19 UTC |
McBarron PaulDirector · See Remarks
|
GrantCommon Stock | 31,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-009914 · tm235262-3_4seq1.xml · nonDerivative · entry 1 McBarron Paul · CIK 0001357397 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,492 F1 · shares: The reporting person received an award of 31,200 restricted stock units on January 31, 2023, which shall vest in full on January 31, 2026, provided, however, that if certain clinical milestones are achieved then such restricted stock units shall vest in full earlier in connection with such achievement. F2 · balance_after: Includes 292 shares of common stock and 31,200 restricted stock units. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 21:18 UTC |
Rombotis Spiro GeorgeDirector · President and CEO
|
GrantCommon Stock | 57,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-009910 · tm235262-2_4seq1.xml · nonDerivative · entry 1 Rombotis Spiro George · CIK 0001357396 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,588 F1 · shares: The reporting person received an award of 57,600 restricted stock units on January 31, 2023, which shall vest in full on January 31, 2026, provided, however, that if certain clinical milestones are achieved then such restricted stock units shall vest in full earlier in connection with such achievement. F2 · balance_after: Includes 4,988 shares of common stock and 57,600 restricted stock units. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 21:17 UTC |
Kirschbaum MarkChief Medical Officer
|
GrantCommon Stock | 31,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-009908 · tm235262-1_4seq1.xml · nonDerivative · entry 1 Kirschbaum Mark · CIK 0001830211 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,200 F1 · shares: The reporting person received an award of 31,200 restricted stock units on January 31, 2023, which shall vest in full on January 31, 2026, provided, however, that if certain clinical milestones are achieved then such restricted stock units shall vest in full earlier in connection with such achievement. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:39 UTC |
Ferguson Kenneth M.Director
|
GrantStock Option (right to buy) · Derivative | 47,467 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001104659-22-071945 · tm2218645d8_4.xml · derivative · entry 2 Ferguson Kenneth M. · CIK 0001934344 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,467 Underlying: Common Stock · 47,467 shares Expires 2032-06-14 F2 · price: The option will vest and become exercisable in equal monthly installments for thirty-six months beginning on the date of the grant, which is June 14, 2022, subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date. F3 · price: These options were granted to Mr. Ferguson for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:39 UTC |
Ferguson Kenneth M.Director
|
GrantCommon Stock | 27,733 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-071945 · tm2218645d8_4.xml · nonDerivative · entry 1 Ferguson Kenneth M. · CIK 0001934344 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,733 F1 · shares: The Reporting Person received an award of 27,733 restricted stock units on June 14, 2022, which shall vest in three equal installments on June 14, 2023, June 14, 2024, and June 14, 2025. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:13 UTC |
Walker Karin LDirector
|
GrantStock Option (right to buy) · Derivative | 31,645 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001104659-22-071903 · tm2218645-6_4seq1.xml · derivative · entry 2 Walker Karin L · CIK 0001559422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,645 Underlying: Common stock · 31,645 shares Expires 2032-06-14 F2 · price: These options were granted to Ms. Walker for her services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:13 UTC |
Walker Karin LDirector
|
GrantCommon Stock | 15,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-071903 · tm2218645-6_4seq1.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,383 F1 · shares: The reporting person received an award of 15,822 restricted stock units on June 14, 2022, which shall vest in full on June 14, 2023. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:12 UTC |
Spiegel Robert J.Director
|
GrantStock Option (right to buy) · Derivative | 31,645 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001104659-22-071900 · tm2218645-5_4seq1.xml · derivative · entry 2 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,645 Underlying: Common Stock · 31,645 shares Expires 2032-06-14 F2 · price: These options were granted to Dr. Spiegel for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:12 UTC |
Spiegel Robert J.Director
|
GrantCommon Stock | 15,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-071900 · tm2218645-5_4seq1.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,196 F1 · shares: The reporting person received an award of 15,822 restricted stock units on June 14, 2022, which shall vest in full on June 14, 2023. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:11 UTC |
Sems LloydDirector
|
GrantStock Option (right to buy) · Derivative | 31,645 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001104659-22-071898 · tm2218645-4_4seq1.xml · derivative · entry 2 Sems Lloyd · CIK 0001436850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,645 Underlying: Common Stock · 31,645 shares Expires 2032-06-14 F2 · price: These options were granted to Mr. Sems for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:11 UTC |
Sems LloydDirector
|
GrantCommon Stock | 15,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-071898 · tm2218645-4_4seq1.xml · nonDerivative · entry 1 Sems Lloyd · CIK 0001436850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,196 F1 · shares: The reporting person received an award of 15,822 restricted stock units on June 14, 2022, which shall vest in full on June 14, 2023. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:11 UTC |
SCHWARTZ BRIANDirector
|
GrantStock Option (right to buy) · Derivative | 31,645 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001104659-22-071895 · tm2218645-3_4seq1.xml · derivative · entry 2 SCHWARTZ BRIAN · CIK 0001431322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,645 Underlying: Common Stock · 31,645 shares Expires 2032-06-14 F2 · price: These options were granted to Dr. Schwartz for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:11 UTC |
SCHWARTZ BRIANDirector
|
GrantCommon Stock | 15,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-071895 · tm2218645-3_4seq1.xml · nonDerivative · entry 1 SCHWARTZ BRIAN · CIK 0001431322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,383 F1 · shares: The reporting person received an award of 15,822 restricted stock units on June 14, 2022, which shall vest in full on June 14, 2023. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:10 UTC |
BARKER SAM LDirector
|
GrantStock Option (right to buy) · Derivative | 31,645 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001104659-22-071892 · tm2218645-1_4seq1.xml · derivative · entry 2 BARKER SAM L · CIK 0001226877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,645 Underlying: Common Stock · 31,645 shares Expires 2032-06-14 F2 · price: These options were granted to Dr. Barker for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:10 UTC |
BARKER SAM LDirector
|
GrantCommon Stock | 15,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-071892 · tm2218645-1_4seq1.xml · nonDerivative · entry 1 BARKER SAM L · CIK 0001226877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,196 F1 · shares: The reporting person received an award of 15,822 restricted stock units on June 14, 2022, which shall vest in full on June 14, 2023. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:11 UTC |
HENNEY CHRISTOPHER SDirector
|
GrantStock Option (right to buy) · Derivative | 31,645 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001104659-22-071893 · tm2218645-2_4seq1.xml · derivative · entry 2 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,645 Underlying: Common Stock · 31,645 shares Expires 2032-06-14 F2 · price: These options were granted to Dr. Henney for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:11 UTC |
HENNEY CHRISTOPHER SDirector
|
GrantCommon Stock | 15,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-071893 · tm2218645-2_4seq1.xml · nonDerivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,196 F1 · shares: The reporting person received an award of 15,822 restricted stock units on June 14, 2022, which shall vest in full on June 14, 2023. Read SEC document |
| June 14, 2022 Filed Jun 17, 2022 20:06 UTC Amendment |
Ferguson Kenneth M.Director
|
GrantStock Option (right to buy) · Derivative | 47,467 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001104659-22-072381 · tm2218810-1_4a.xml · derivative · entry 2 Ferguson Kenneth M. · CIK 0001934344 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,467 Underlying: Common Stock · 47,467 shares Expires 2032-06-14 F3 · price: The option will vest and become exercisable in equal monthly installments for thirty-six months beginning on the date of the grant, which is June 14, 2022, subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date. F4 · price: These options were granted to Mr. Ferguson for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 14, 2022 Filed Jun 17, 2022 20:06 UTC Amendment |
Ferguson Kenneth M.Director
|
GrantCommon Stock | 23,733 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-072381 · tm2218810-1_4a.xml · nonDerivative · entry 1 Ferguson Kenneth M. · CIK 0001934344 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,733 F1 · shares: The Reporting Person received an award of 23,733 restricted stock units on June 14, 2022, which shall vest in three equal installments on June 14, 2023, June 14, 2024, and June 14, 2025. F2 · shares: This Form 4 is being amended to correct a typographical error in the number of restricted stock units granted to the Reporting Person on June 14, 2022. 23,733 shares of restricted stock units were granted to the Reporting Person. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 21:19 UTC |
McBarron PaulDirector · See Remarks
|
GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001104659-21-150001 · tm2135363d2_4.xml · derivative · entry 1 McBarron Paul · CIK 0001357397 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-12-13 F2 · price: These securities were granted as part of the Issuer's annual compensation review to executive officers. F1 · derivative.exercise_date: These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 21:20 UTC |
Rombotis Spiro GeorgeDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 190,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001104659-21-150003 · tm2135363d3_4.xml · derivative · entry 1 Rombotis Spiro George · CIK 0001357396 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 90,000 shares Expires 2031-12-13 F2 · price: These securities were granted as part of the Issuer's annual compensation review to executive officers. F1 · derivative.exercise_date: These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 21:18 UTC |
Kirschbaum MarkChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001104659-21-150000 · tm2135363d1_4.xml · derivative · entry 1 Kirschbaum Mark · CIK 0001830211 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-12-13 F2 · price: These securities were granted as part of the Issuer's annual compensation review to executive officers. F1 · derivative.exercise_date: These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 21:16 UTC Amendment |
Rombotis Spiro GeorgeDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 190,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001104659-21-150527 · tm2135616d1_4a.xml · derivative · entry 1 Rombotis Spiro George · CIK 0001357396 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2031-12-13 F2 · price: These securities were granted as part of the Issuer's annual compensation review to executive officers. F1 · derivative.exercise_date: These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis. F3 · derivative.underlying_shares: This Form 4 is being amended to correct a typographical error in the number of shares of Common Stock underlying the options granted to the reporting person on December 13, 2021. 190,000 shares of Common Stock underlie the granted options. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 21:07 UTC |
BARKER SAM LDirector
|
SaleCommon Stock | 12 | $3.57 | $42.86 |
DisclosureSEC source: 0001104659-21-145913 · tm2134438-1_4seq1.xml · nonDerivative · entry 1 BARKER SAM L · CIK 0001226877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,374 F1 · shares: The reporting person sold 12 shares of common stock on November 30, 2021. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 21:05 UTC |
Rombotis Spiro GeorgeDirector · President and CEO
|
PurchaseCommon Stock | 4,000 | $4.50 | $18,000.00 |
DisclosureSEC source: 0001104659-21-142474 · tm2133647-1_4seq1.xml · nonDerivative · entry 1 Rombotis Spiro George · CIK 0001357396 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,988 F1 · shares: The reporting person purchased 4,000 shares of common stock on November 18, 2021. Read SEC document |
| August 24, 2021 Filed Aug 25, 2021 20:16 UTC |
BARKER SAM LDirector
|
PurchaseCommon Stock | 1,000 | $5.00 | $5,000.00 |
DisclosureSEC source: 0001104659-21-109337 · tm2125937-1_4seq1.xml · nonDerivative · entry 1 BARKER SAM L · CIK 0001226877 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,386 F1 · shares: The reporting person purchased 1,000 shares of common stock on August 24, 2021. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:09 UTC |
Hradsky Gregory T.Director
|
GrantStock Option (right to buy) · Derivative | 4,748 | $0.00 Strike: $6.69 | $0.00 |
DisclosureSEC source: 0001104659-21-082605 · tm2119990d7_4.xml · derivative · entry 2 Hradsky Gregory T. · CIK 0001439092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,748 Underlying: Common Stock · 4,748 shares Expires 2031-06-15 F2 · price: These options were granted to Mr. Hradsky for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:09 UTC |
Hradsky Gregory T.Director
|
GrantCommon Stock | 2,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-082605 · tm2119990d7_4.xml · nonDerivative · entry 1 Hradsky Gregory T. · CIK 0001439092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,374 F1 · shares: The reporting person received an award of 2,374 restricted stock units on June 15, 2021, which shall vest in full on June 15, 2022. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:08 UTC |
Sems LloydDirector
|
GrantStock Option (right to buy) · Derivative | 4,748 | $0.00 Strike: $6.69 | $0.00 |
DisclosureSEC source: 0001104659-21-082600 · tm2119990d4_4.xml · derivative · entry 2 Sems Lloyd · CIK 0001436850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,748 Underlying: Common Stock · 4,748 shares Expires 2031-06-15 F2 · price: These options were granted to Mr. Sems for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.